Back to results
US 8,044,043 B2Granted
CGRP receptor antagonists
AssigneeBristol-Myers Squibb Company
InventorGuanglin Luo
Life of this patent
Estimating the term…
Abstract
The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine and other headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases such as asthma, and chronic obstructive pulmonary disease (COPD).
Claims21
A compound of Formula I
- where:
- R′ is hydrogen, cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, alkylSO2, amino, alkylamino, dialkylamino, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-alkylpiperazinyl, or morpholinyl;
- R2 is piperidinyl substituted with 1 substituent selected from the group consisting of
- R3 is hydrogen, halo, cyano, alkyl, haloalkyl, alkoxy, or haloalkoxy;
- R4 is hydrogen, halo, cyano, alkyl, haloalkyl, alkoxy, or haloalkoxy;
- Ar1 is phenyl substituted with 0-3 substituents selected from the group consisting of cyano, halo, alkyl, haloalkyl, alkoxy, haloalkoxy, and alkylSO2;
- X is O, CH2, or NH;
- and
- Y is a bond, O, CH2, or NH;
- or a pharmaceutically acceptable salt thereof.
7 more elements
The compound
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.